Compare SOC & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOC | DMRA |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | 200 | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | SOC | DMRA |
|---|---|---|
| Price | $10.15 | $22.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $17.33 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 4.4M | 385.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $16.50 |
| 52 Week High | $32.18 | $28.76 |
| Indicator | SOC | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 41.75 |
| Support Level | $6.75 | $18.59 |
| Resistance Level | $15.27 | $27.70 |
| Average True Range (ATR) | 1.19 | 1.99 |
| MACD | -0.31 | -0.06 |
| Stochastic Oscillator | 12.57 | 36.16 |
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.